Modafinil Provigil is a drug that supports wakefulness that is permitted by the USA’s Food and Drug Administration (FDA) for the treatment of excessive daytime sleepiness associated with obstructive sleep apnea, shift work sleep disorder and narcolepsy.
U.S.A’s Food and Drug Administration approve Modafinil Provigil only to cure shift work sleep disorder, narcolepsy, and as for treatment of obstructive sleep apnea. It is also permitted for other hypersomnias, like idiopathic hypersomnia in some countries. Only 200 mg of dosage is the usual prescribed for these disorders each day.
Modafinil Provigil is generally taken at once in the morning or twice, once in the morning and the other at midday for problems other than shift work sleep disorder. It is usually not advised to take Modafinil Provigil beyond noon: it is a strong drug with a half-life of fifteen hours. There is a risk of sleep disturbance when taking the drug during the later part of the afternoon
The European Medicines Agency only suggests that new patient prescriptions take the drug if sleepiness associated with narcolepsy as there is the risk for neuropsychiatric disorders hypersensitivity reactions or development of the skin. The regulation does not require patients already under treatment to quit taking the drug as any serious side effects will generally appear within the 1st twelve weeks.
Modafinil Provigil was seen as a successful treatment for attention deficit hyperactivity disorder (ADHD); however, it was found unfit for the children by the FDA for that purpose, in 2006. It was abandoned basically due to two cases of skin rash which were serious. It was alleged to have been Stevens–Johnson syndrome or Erythema multiforme, among 933 participants receiving the drug. Children are discouraged to use Cephalon’s own label for Provigil for any purpose.
Another effective, but not permitted uses include the treatment of schizophrenia , Parkinson’s disease , cocaine dependence , opiate, bipolar depression , depression, and ,and disease-related fatigue, as well as fatigue which is a side effect of other medication. Seasonal affective disorder will also be well tolerated and effective in patients with the use of Modafinil Provigil .
General healthy participants between the ages of thirty and forty four showed general improvement in mood as well as alertness with a randomized double-blind study of Modafinil Provigil ., inpatient trial , crossover , randomized, counterbalanced of Modafinil Provigil four hundred mg was administered as well as a placebo was given to the control group in the three-day study. Adjunctive use of modafine was concluded to have general mood-elevating effects in treatment-resistant depression.
Weight loss effect/appetite reducing was observed in studies on Modafinil Provigil. In 2008, a small study of people performing genuine shift work saw the effect as an eighteen percent decrease in total caloric intake of two hundred mg/day, and a thirty eight percent decrease of four hundred mg/day. However, the prescribed information on Provigil shows that there were no scientifically relevant differences in body weight in patients treated with PROVIGIL as compared to placebo-treated patients in the placebo-controlled trials.